Professor Steve Jackson, FRS FMedSci (Chief Executive and Chief Scientific Officer)
Steve is the University of Cambridge Frederick James Quick Professor of Biology and Head of Cancer Research UK Laboratories at the Wellcome Trust/Cancer Research UK Gurdon Institute. He is a world expert in DNA repair and DNA-damage signaling. He has founded three companies, one of which, KuDOS Pharmaceuticals, developed the anti-cancer drug olaparib/Lynparza®. Steve is a fellow of the Royal Society, and has received various awards, including the 2015 Gagna and van Heck Prize for Medicine, the 2016 King Faisal International Prize for Science, the 2016 AH. Heineken Prize for Medicine, and the 2019 Fondation ARC Léopold Griffuel Award for Translational and Clinical Research.
Dr Gabriel Balmus (co-founder and consultant)
Gabriel is Principal Investigator at the UK Dementia Research Institute at the University of Cambridge and the Department of Clinical Neurosciences. After training in Veterinary Medicine, Gabriel carried out PhD and post-doctoral training in the laboratory of Robert Weiss at Cornell University, USA. From 2013-2018, Gabriel established and led the Steve Jackson laboratory at the Wellcome Sanger Institute. Gabriel’s varied and deep experience are of great value for Adrestia’s current programmes and platforms.
Dr Yaron Galanty (co-founder and consultant)
Yaron is a Senior Research Associate in the Gurdon Institute, University of Cambridge. Having carried out his PhD training in the laboratory of Prof. Yosef Shiloh in Tel Aviv, Israel, Yaron has played key roles in shaping DNA-repair research in the Jackson group through his own research and via his mentoring of other scientists. He has extensive experience in consulting for biotechnology start-ups. His wealth of expertise in multiple areas of cell and molecular biology allow him to play key roles in advising and shaping the science of Adrestia.
Professor Rafael Carazo Salas (co-founder and consultant)
Rafael is Professor of Biomedical Sciences at the University of Bristol. Trained as a physicist, mathematician and cell biologist, he did his PhD at EMBL Heidelberg and postdoctoral work with Sir Paul Nurse at CRUK LRI and Rockefeller University before holding Group Leader positions in ETH Zurich and Cambridge. Rafael is a prominent international figure in the fields of systems microscopy, microscopy phenomics and quantitative cell biology. He brings to Adrestia key know-how in pipelining, high-throughput/high-content microscopy screening and Big Data analytics.